Back ground: One of the most prevailing diseases that required effective drug as therapeutic purposes
is cardiac related illness includes myocardial infarction Current scenario makes enzyme to raises their sector
towards therapeutic as effective active component for such diseases.
Objectives: The main aim of the study was to isolate, screen, characterize and produce an extracellular thrombolytic
protease from marine actinomycetes.
Methods: Marine actinomycete was isolated and characterized on the basis of morphological, biochemical, and
molecular characterization. The primary screening for protease activity was done by casein hydrolysis method
followed by radial caseinolytic assay. The actinoprotease was partially purified using ammonium sulfate precipitation
technique followed by dialysis and Sephadex G-50 gel permeation chromatography.
Results: 16srDNA sequencing and BLAST search analysis of the sequence revealed close affiliation with
Streptomyces genera and identified as Streptomyces violaceus VITYGM with 99% similarity. The specific activity
of purified protease was found to be 1437 units/mg along with purification fold up to 1.5 times. The blood
clot lysis activity was compared with the standard and found to lyse the blood clot with 97.43%. Till now very
less evidences have been reported on actinoprotease. A single peak at retention time 0.9 min observed on high
performance liquid chromatography (HPLC) confirmed the homogeneity of the preparation.
Conclusion: This is the first study to report on actinoprotease from Streptomyces violaceus VITYGM. This
study emphasizes the potency of novel actinoproteases as active compound in drugs for the treatment of cardiovascular